{"disease":{"id":"mds","name":"mds"},"drugs":{"marketed":[{"drug_id":"imetelstat","indication_name":"Low- to Intermediate-1 Risk MDS with Transfusion-Dependent Anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."},{"drug_id":"cedazuridine","indication_name":"Myelodysplastic Syndromes (MDS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEDAZURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"DNA methyltransferase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":45,"revenue":null,"mechanism":"Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation and cellular differentiation or apoptosis."},{"drug_id":"treosulfan","indication_name":"Allogeneic HSCT in MDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trecondi","generic_name":"TREOSULFAN","company_name":"Medexus","drug_phase":"marketed","molecular_target":"","drug_class":"treosulfan","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl941","indication_name":"MDS/MPD with PDGFR Rearrangements","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01252485","title":"Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02775383","title":"The National Myelodysplastic Syndromes (MDS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":2115,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07465029","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06681363","title":"Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT04212390","title":"Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","has_results":false},{"nct_id":"NCT03335943","title":"Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Chinese Society of Hematology","has_results":false},{"nct_id":"NCT07397013","title":"Adjustment Technique for Occlusal Stabilizing Splint","phase":"NA","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT01929408","title":"Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":665,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT00923442","title":"Biology Studies of Hematologic Cancers","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":550,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07355478","title":"Asia Myelodysplastic Syndrome (MDS) Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06783530","title":"Psychological and Clinical Outcomes of Splint Therapy with and Without Doctor-Patient Communication in TMD Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":435,"lead_sponsor_name":"Soaad Tolba Mohammed Tolba Badawi","has_results":false},{"nct_id":"NCT06971185","title":"A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01261312","title":"SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":414,"lead_sponsor_name":"Astex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02016781","title":"Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":384,"lead_sponsor_name":"Medical College of Wisconsin","has_results":true},{"nct_id":"NCT02562443","title":"Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":372,"lead_sponsor_name":"Traws Pharma, Inc.","has_results":false},{"nct_id":"NCT02158858","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT07045441","title":"Development and Validation of a Temporomandibular Disorders (TMDs) Adherence Questionnaire","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Soaad Tolba Mohammed Tolba Badawi","has_results":false},{"nct_id":"NCT06211166","title":"Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04184505","title":"Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":274,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT00614523","title":"Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04547049","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":232,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07318662","title":"Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":224,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06267898","title":"Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML","phase":"","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"European Society for Blood and Marrow Transplantation","has_results":false},{"nct_id":"NCT00309842","title":"Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT07319793","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05674539","title":"Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT00887068","title":"Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07396480","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03263091","title":"Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":184,"lead_sponsor_name":"Kyntra Bio","has_results":true},{"nct_id":"NCT05175508","title":"Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06594965","title":"A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":176,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT02214407","title":"Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Groupe Francophone des Myelodysplasies","has_results":false},{"nct_id":"NCT02790515","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03745716","title":"APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"Aprea Therapeutics","has_results":true},{"nct_id":"NCT02632708","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT05181735","title":"Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Groupe Francophone des Myelodysplasies","has_results":false},{"nct_id":"NCT01362140","title":"Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03173248","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT05998408","title":"JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":145,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT01861106","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03647800","title":"Study of APVO436 in Patients With AML or MDS","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":136,"lead_sponsor_name":"Aptevo Research and Development LLC","has_results":false},{"nct_id":"NCT00528983","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02103478","title":"Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Astex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT00796068","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06972641","title":"Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Ruijin Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}